{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:02:38Z","timestamp":1771851758738,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:00:00Z","timestamp":1755907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Beijing Municipal Science and Technology Commission"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41409-025-02699-8","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T10:21:14Z","timestamp":1755944474000},"page":"1472-1479","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study"],"prefix":"10.1038","volume":"60","author":[{"given":"Si-Qi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0267-1081","authenticated-orcid":false,"given":"Lan-Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1253-7465","authenticated-orcid":false,"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-6792","authenticated-orcid":false,"given":"Xiao-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Rong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1856-2231","authenticated-orcid":false,"given":"Yu-Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen-Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9881-7945","authenticated-orcid":false,"given":"Xiao-Dong","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6124-6050","authenticated-orcid":false,"given":"Ying-Jun","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,23]]},"reference":[{"key":"2699_CR1","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","volume":"9","author":"YJ Chang","year":"2022","unstructured":"Chang YJ, Pei XY, Huang XJ. Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol. 2022;9:e919\u2013e929. https:\/\/doi.org\/10.1016\/S2352-3026(22)00293-9.","journal-title":"Lancet Haematol"},{"key":"2699_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.20.01170","volume":"39","author":"AK Burnett","year":"2021","unstructured":"Burnett AK, Russell NH, Hills RK, Knapper S, Freeman S, Huntly B, et al. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. J Clin Oncol. 2021;39:890\u2013901. https:\/\/doi.org\/10.1200\/JCO.20.01170.","journal-title":"J Clin Oncol"},{"key":"2699_CR3","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1038\/s41409-021-01227-8","volume":"56","author":"JR Passweg","year":"2021","unstructured":"Passweg JR, Baldomero H, Chabannon C, Basak GW, de la Camara R, Corbacioglu S, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transpl. 2021;56:1651\u201364. https:\/\/doi.org\/10.1038\/s41409-021-01227-8.","journal-title":"Bone Marrow Transpl"},{"key":"2699_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H Dohner","year":"2022","unstructured":"Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377. https:\/\/doi.org\/10.1182\/blood.2022016867.","journal-title":"Blood"},{"key":"2699_CR5","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","volume":"378","author":"M Jongen-Lavrencic","year":"2018","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1716863.","journal-title":"N Engl J Med"},{"key":"2699_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13045-017-0502-3","volume":"10","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Wang Y, Liu YR, Xu LP, Zhang XH, Chen H, et al. Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis. J Hematol Oncol. 2017;10:134 https:\/\/doi.org\/10.1186\/s13045-017-0502-3.","journal-title":"J Hematol Oncol"},{"key":"2699_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-54254-6","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhang S, Feng R, Xiao K, Wang T, Bai J, et al. Longitudinal ultra-sensitive mutation burden sequencing for precise minimal residual disease assessment in AML. Nat Commun. 2024;15:9853 https:\/\/doi.org\/10.1038\/s41467-024-54254-6.","journal-title":"Nat Commun"},{"key":"2699_CR8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/bmt.2012.139","volume":"48","author":"SA Buckley","year":"2013","unstructured":"Buckley SA, Appelbaum FR, Walter RB. Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia. Bone Marrow Transpl. 2013;48:630\u201341. https:\/\/doi.org\/10.1038\/bmt.2012.139.","journal-title":"Bone Marrow Transpl"},{"key":"2699_CR9","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","volume":"31","author":"SD Freeman","year":"2013","unstructured":"Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123\u201331. https:\/\/doi.org\/10.1200\/JCO.2013.49.1753.","journal-title":"J Clin Oncol"},{"key":"2699_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/17474086.2023.2285985","volume":"16","author":"SQ Li","year":"2023","unstructured":"Li SQ, Chen M, Huang XY, Wang H, Chang YJ. Challenges facing minimal residual disease testing for acute myeloid leukemia and promising strategies to overcome them. Expert Rev Hematol. 2023;16:981\u201390. https:\/\/doi.org\/10.1080\/17474086.2023.2285985.","journal-title":"Expert Rev Hematol"},{"key":"2699_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1182\/blood.2021014604","volume":"140","author":"SQ Li","year":"2022","unstructured":"Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022;140:516\u201320. https:\/\/doi.org\/10.1182\/blood.2021014604.","journal-title":"Blood"},{"key":"2699_CR12","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3324\/haematol.2011.047894","volume":"96","author":"F Vergez","year":"2011","unstructured":"Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34+CD38low\/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792\u20138. https:\/\/doi.org\/10.3324\/haematol.2011.047894.","journal-title":"Haematologica"},{"key":"2699_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","volume":"33","author":"W Zeijlemaker","year":"2019","unstructured":"Zeijlemaker W, Grob T, Meijer R, Hanekamp D, Kelder A, Carbaat-Ham JC, et al. CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. Leukemia. 2019;33:1102\u201312. https:\/\/doi.org\/10.1038\/s41375-018-0326-3.","journal-title":"Leukemia"},{"key":"2699_CR14","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1182\/blood.2022019160","volume":"141","author":"LL Ngai","year":"2023","unstructured":"Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland M, Fayed M, et al. Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial. Blood. 2023;141:2657\u201361. https:\/\/doi.org\/10.1182\/blood.2022019160.","journal-title":"Blood"},{"key":"2699_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/cyto.b.22148","volume":"106","author":"S Mizuta","year":"2024","unstructured":"Mizuta S, Iwasaki M, Bandai N, Yoshida S, Watanabe A, Takashima H, et al. Flow cytometric analysis of CD34(+) CD38(-) cells; cell frequency and immunophenotype based on CD45RA expression pattern. Cytom B Clin Cytom. 2024;106:35\u201344. https:\/\/doi.org\/10.1002\/cyto.b.22148.","journal-title":"Cytom B Clin Cytom"},{"key":"2699_CR16","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.1158\/1078-0432.CCR-05-0468","volume":"11","author":"A van Rhenen","year":"2005","unstructured":"van Rhenen A, Feller N, Kelder A, Westra AH, Rombouts E, Zweegman S, et al. High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res. 2005;11:6520\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0468.","journal-title":"Clin Cancer Res"},{"key":"2699_CR17","doi-asserted-by":"publisher","first-page":"e107587","DOI":"10.1371\/journal.pone.0107587","volume":"9","author":"M Terwijn","year":"2014","unstructured":"Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, et al. Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014;9:e107587 https:\/\/doi.org\/10.1371\/journal.pone.0107587.","journal-title":"PLoS One"},{"key":"2699_CR18","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41375-024-02203-z","volume":"38","author":"MF van Spronsen","year":"2024","unstructured":"van Spronsen MF, Van Gassen S, Duetz C, Westers TM, Saeys Y, van de Loosdrecht AA. Myelodysplastic neoplasms dissected into indolent, leukaemic and unfavourable subtypes by computational clustering of haematopoietic stem and progenitor cells. Leukemia. 2024;38:1365\u201377. https:\/\/doi.org\/10.1038\/s41375-024-02203-z.","journal-title":"Leukemia"},{"key":"2699_CR19","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41375-024-02148-3","volume":"38","author":"E Klyuchnikov","year":"2024","unstructured":"Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, et al. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024;38:386\u20138. https:\/\/doi.org\/10.1038\/s41375-024-02148-3.","journal-title":"Leukemia"},{"key":"2699_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ajh.24663","volume":"92","author":"M Jentzsch","year":"2017","unstructured":"Jentzsch M, Bill M, Nicolet D, Leiblein S, Schubert K, Pless M, et al. Prognostic impact of the CD34+\/CD38- cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation. Am J Hematol. 2017;92:388\u201396. https:\/\/doi.org\/10.1002\/ajh.24663.","journal-title":"Am J Hematol"},{"key":"2699_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/leu.2015.252","volume":"30","author":"W Zeijlemaker","year":"2016","unstructured":"Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJ, Scholten WJ, Snel AN, Veldhuizen D, et al. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016;30:439\u201346. https:\/\/doi.org\/10.1038\/leu.2015.252.","journal-title":"Leukemia"},{"key":"2699_CR22","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1182\/blood-2015-02-627786","volume":"125","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956\u201362. https:\/\/doi.org\/10.1182\/blood-2015-02-627786.","journal-title":"Blood"},{"key":"2699_CR23","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1200\/JCO.2015.63.8817","volume":"34","author":"YJ Chang","year":"2016","unstructured":"Chang YJ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. Controlled, randomized, open-label trial of risk-stratified corticosteroid prevention of acute graft-versus-host disease after haploidentical transplantation. J Clin Oncol. 2016;34:1855\u201363. https:\/\/doi.org\/10.1200\/JCO.2015.63.8817.","journal-title":"J Clin Oncol"},{"key":"2699_CR24","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s11427-019-1610-2","volume":"63","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu QF, Wu DP, Wang JB, Zhang X, Wang HX, et al. Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study. Sci China Life Sci. 2020;63:1552\u201364. https:\/\/doi.org\/10.1007\/s11427-019-1610-2.","journal-title":"Sci China Life Sci"},{"key":"2699_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/j.1751-553X.2007.00865.x","volume":"29","author":"F Aydin","year":"2007","unstructured":"Aydin F, Oguz F, Onal AE, Bilgen H, Oguz R, Anak S, et al. FISH detection of chimerism in pediatric hematopoietic stem cell transplantation. Int J Lab Hematol. 2007;29:208\u201314. https:\/\/doi.org\/10.1111\/j.1751-553X.2007.00865.x.","journal-title":"Int J Lab Hematol"},{"key":"2699_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bmt.2014.158","volume":"49","author":"XY Qin","year":"2014","unstructured":"Qin XY, Li GX, Qin YZ, Wang Y, Wang FR, Liu DH, et al. Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT. Bone Marrow Transpl. 2014;49:1269\u201377. https:\/\/doi.org\/10.1038\/bmt.2014.158.","journal-title":"Bone Marrow Transpl"},{"key":"2699_CR27","doi-asserted-by":"publisher","first-page":"E659","DOI":"10.1002\/ajh.24910","volume":"92","author":"YJ Chang","year":"2017","unstructured":"Chang YJ, Zhao XS, Wang Y, Liu YR, Xu LP, Zhang XH, et al. Effects of pre- and post-transplantation minimal residual disease on outcomes in pediatric patients with acute myeloid leukemia receiving human leukocyte antigen-matched or mismatched related donor allografts. Am J Hematol. 2017;92:E659\u2013E661. https:\/\/doi.org\/10.1002\/ajh.24910.","journal-title":"Am J Hematol"},{"key":"2699_CR28","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391. https:\/\/doi.org\/10.1182\/blood-2017-09-801498.","journal-title":"Blood"},{"key":"2699_CR29","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367. https:\/\/doi.org\/10.1182\/blood.2021013626.","journal-title":"Blood"},{"key":"2699_CR30","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1200\/JCO.20.00150","volume":"38","author":"YJ Chang","year":"2020","unstructured":"Chang YJ, Wu DP, Lai YR, Liu QF, Sun YQ, Hu J, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020;38:3367\u201376. https:\/\/doi.org\/10.1200\/JCO.20.00150.","journal-title":"J Clin Oncol"},{"key":"2699_CR31","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.bbmt.2014.12.031","volume":"21","author":"HM Shulman","year":"2015","unstructured":"Shulman HM, Cardona DM, Greenson JK, Hingorani S, Horn T, Huber E, et al. NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. Biol Blood Marrow Transpl. 2015;21:589\u2013603. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.031.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2699_CR32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","volume":"17","author":"International CLLIPIwg.","year":"2016","unstructured":"International CLLIPIwg. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17:779\u201390. https:\/\/doi.org\/10.1016\/S1470-2045(16)30029-8.","journal-title":"Lancet Oncol"},{"key":"2699_CR33","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768\u201378. https:\/\/doi.org\/10.1200\/JCO.20.02308.","journal-title":"J Clin Oncol"},{"key":"2699_CR34","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273\u201383. https:\/\/doi.org\/10.1200\/JCO.19.03011.","journal-title":"J Clin Oncol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02699-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T15:20:18Z","timestamp":1762183218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,23]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2699"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02699-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,23]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Research was performed in compliance with all applicable guidelines and regulations. The study was performed in accordance with Declaration of Helsinki and was approved by Institutional Review Board of Peking University (Ethics Committee of Peking University People\u2019s Hospital), the reference number was 2017PHB033-01.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All of the patients who were included in the study provided signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}